4वां वार्षिक ईसीडी मेडिकल संगोष्ठी पेरिस, फ्रांस

जेवियर सोलानिच, एमडी, पीएचडी
बुलेवार्ड डी एल'हॉपिटा
पेरिस, फ्रांस
1 अप्रैल, 2016

पेरिस मेडिकल सिम्पोजियम ग्रुप पिक्चर 2016

संगोष्ठी का सारांश

Erdheim-Chester Disease Global Alliance को इस वर्ष पेरिस, फ्रांस के Hôpital Pitié-Salpêtrière में 15 सितंबर, 2016 को आयोजित चौथे वार्षिक अंतर्राष्ट्रीय ECD मेडिकल संगोष्ठी में दी गई प्रस्तुतियों का सारांश प्रदान करते हुए प्रसन्नता हो रही है। इस बैठक ने चिकित्सा पेशेवरों को ECD अनुसंधान पर सहयोग करने, चिकित्सा निष्कर्षों को साझा करने और रोगी देखभाल पर चर्चा करने का अवसर दिया। इस वर्ष के सह-मेजबान, प्रोफेसर जूलियन हारोचे, MD, PhD; पैनल चर्चा के दौरान अपना डेटा और विशेषज्ञता साझा करने वाले सभी प्रस्तुतकर्ताओं; ECD के बारे में अधिक जानने में रुचि रखने वाले सभी उपस्थित लोगों; और इस कार्यक्रम की योजना बनाने और इसे सफल बनाने में शामिल सभी लोगों को धन्यवाद। उन स्वयंसेवकों को विशेष धन्यवाद जिन्होंने समुदाय के लिए और उन पेशेवरों के लिए यह सारांश तैयार किया जो उपस्थित होने में असमर्थ थे।

संगोष्ठी के कार्यक्रम के एजेंडा सहित

प्रस्तुतियों

2016 की बैठक में निम्नलिखित प्रस्तुतियाँ दी गई थीं। सभी प्रकाशित ECD संबंधित वीडियो देखने के लिए ECD ग्लोबल अलायंस यूट्यूब चैनल पर जाएँ।

PresenterPresentation SlidesVideos
Prof. Julien Haroche, MD, PhDWelcomeWelcome
Omar Abdel-Wahab, MD, PhD and Benjamin Durham, MD;Insights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine Models
Lorenzo Dagna, MD, PhDCCL18 in Erdheim-Chester Disease: Potential Implications in the PathogenesisNot available
Matthew Collin, MDThe Hematopoietic Origin of Adult HistiocytosisNot available
Matthias Papo, MDErdheim-Chester disease is frequently associated with myeloproliferative neoplasms and myelodysplastic syndromes: a systematic clinical and molecular series of 189 patientsNot available
Fleur Cohen-Aubart, MD & Wilfred Le Goff, MDMarked alteration of circulating immune cells in Erdheim-Chester disease in a large single-center series of 46 patientsNot available
Roei D. Mazor, MDBiopsy Specimens of Erdheim-Chester Disease PatientsNot available
Filip Janku, MD, PhDClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Tahla Munir, MDA Single- centre Experience of Treating Adult Patients with Langerhans' cell
Histiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease		A Single- centre Experience of Treating Adult Patients with Langerhans' cellHistiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease
Achille Aouba, MD, PhDSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester DiseaseSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester Disease
Tahla Munir, MDSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor VemurafenibSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor Vemurafenib
Fleur Cohen-Aubart, MD and Julien Haroche, MD, PhDThe LOVE trial: preliminary resultsNot available
Juvianee Estrada-Veras, MDDabrafenib and Trametinib as Potential Therapy in BRAF V600E Positive ErdheimChester Disease (ECD): Preliminary ResultsNot available
Eli L. Diamond, MDPhase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Preliminary ResultsNot available
Tahla Munir, MDDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case reportDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case report
Diana Melo, MDSpectrum of Cardiovascular Involvement in Erdheim-Chester Disease Evaluated by Multimodality ImagingNot available
Mark Heaney, MD, Julien Haroche, MD, PhD, Eli L. Diamond, MD, Matthew Collin, MD, Lorenzo Dagna, MD, PhDPanel Discussion: ECD Patient Registry: Community Tool for ResearchPanel Discussion: ECD Patient Registry: Community Tool for Research
Augusto Vaglio, MD, PhD, Juvianee Estrada-Veras, MD, Filip Janku, MD, PhD, Omar Abdel-Wahab, MD, PhD, Javier Martin, MD, PhDPanel Discussion: Proposed ECD GWAS StudyPanel Discussion: Proposed ECD GWAS Study
Corrado Campochiaro, MDManagement of ECD Symptoms and Side Effects of TreatmentsManagement of ECD Symptoms and Side Effects of Treatments
Giulio Cavalli, MDAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester DiseaseAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease
Carine Courtillot, MDEndocrine manifestations in Erdheim-Chester diseaseEndocrine manifestations in Erdheim-Chester disease
Benjamin Durham, MDInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models
Marina Ferrarini, MDTailoring Treatment for Erdheim-Chester Disease: Focus on ECDTailoring Treatment for Erdheim-Chester Disease: Focus on ECD
Ronald Go, MDEfficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)
Filip Janku, MD, PhDEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Javier Martin, MD, PhDFuture Genetic Studies in Erdheim-Chester disease – GWAS StudyFuture Genetic Studies in Erdheim-Chester disease – GWAS Study
Kenneth McClain, MD, PhDElevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?
Augusto Vaglio, MD, PhDMRI evidence of cardiac involvement in Erdheim-Chester diseaseMRI evidence of cardiac involvement in Erdheim-Chester disease
Julien Haroche, MD, PhD & Kathleen BrewerClosingNot available